Goosehead Insurance (NasdaqGS:GSHD) Q4 2025 Earnings call February 17, 2026 04:30 PM ET Company ParticipantsDan Farrell - VP of Capital MarketsMark Jones Jr. - CFO and COOMark Miller - President and CEOConference Call ParticipantsAndrew Andersen - Equity Research AnalystAndrew Kligerman - Equity Research AnalystBrian Meredith - Equity Research AnalystKatie Sakys - Equity Research AnalystMark Hughes - Equity Research AnalystMichael Zaremski - Equity Research AnalystPablo Singzon - Equity Research AnalystPaul ...

Medifast (NYSE:MED) Q4 2025 Earnings call February 17, 2026 04:30 PM ET Company ParticipantsDan Chard - Chairman and CEOJim Maloney - CFONick Johnson - PresidentSteven Zenker - VP of Investor RelationsConference Call ParticipantsJim Salera - Research AnalystOperatorGreetings, and welcome to the Medifast fourth quarter 2025 earnings conference call. At this time, all participants are in a listen-only mode. A brief question and answer session will follow the formal presentation. Should anyone require operator ...

Financial Data and Key Metrics Changes - Adjusted EBITDA increased by 10% on a 4% increase in gross transaction value (GTV) in Q4 2025, reflecting strong execution and cost management [4][11] - Adjusted earnings per share increased by 17% in Q4 and 15% for the full year, driven by higher operating income and lower net interest expense [14] - Full-year GTV increased by 2%, driven by new wins in the automotive sector, partially offset by cyclical pressure in the commercial construction and transportation (CC&T) sector [12][14] Business Line Data and Key Metrics Changes - Automotive GTV increased by 3% in Q4, with unit volumes rising by 2%. Excluding catastrophic impacts, GTV and unit volumes grew approximately 12% and 8%, respectively [11][12] - In the CC&T sector, GTV increased by 9%, with unit volumes growing approximately 10% and average price per lot sold increasing due to improvements in asset mix [12][14] Market Data and Key Metrics Changes - Gross returns or salvage values as a percentage of pre-accident cash values expanded, supporting approximately 7% year-over-year growth in the U.S. insurance average selling price [6] - The inflation differential between automotive repair costs and used vehicle pricing continued to narrow, supporting an increase in the total loss ratio [11] Company Strategy and Development Direction - The company is focused on disciplined execution and strategic progress, prioritizing scale, longevity, and strategic positioning to expand market share and enhance partner relationships [4][5] - A new multi-year agreement with one of the largest partners was signed, reinforcing trust and providing long-term visibility into expected volumes [5][6] - The company plans to roll out the IAA Total Loss Predictor in 2026 to improve vehicle routing efficiency, which is expected to deliver cost savings for partners [8] Management's Comments on Operating Environment and Future Outlook - Management expressed cautious optimism regarding early signs of improvement in seller confidence within the CC&T sector, supported by stabilizing used equipment values and lower interest rates [9] - The outlook for 2026 anticipates full-year GTV growth between 5% and 8%, with a focus on volume-led growth and continued market share gains [15] Other Important Information - The company expects full-year capital expenditures for 2026 to be between $350 million and $400 million, with a mix of one-third on technology-related investments and two-thirds on traditional physical assets [15][38] - The company is committed to ongoing operational excellence and cost savings initiatives to maximize profit flow-through [15][47] Q&A Session Summary Question: Clarification on 2026 guidance and market share capture - Management confirmed that the guidance includes annualization of wins already announced and any additional terms agreed upon [20] Question: Flow-through of GTV to revenue - Management indicated there may be slight pressure on the take rate but remains optimistic about unit economics and volume growth [22] Question: Improvement in CC&T sector - Management noted early signs of improvement in partner conversations, indicating potential for a return to a normalized cycle [26] Question: Details on the total loss predictor - The total loss predictor aims to enhance efficiency by determining vehicle status at the scene of an accident, potentially reducing costs associated with storage and rental fees [28] Question: AI development among competitors - Management acknowledged varying capabilities among insurance carriers regarding AI development, emphasizing their role in providing integrated solutions [35] Question: Capital allocation strategy - Management is focused on debt reduction, business investment, and evaluating share repurchase opportunities as part of their capital allocation strategy [53] Question: Impact of autonomous vehicles - Management does not foresee immediate risks from autonomous vehicles but acknowledges potential long-term changes in collision rates and vehicle ownership [57] Question: Total salvage volumes outlook - Management expects to continue gaining market share and growing faster than the market, without providing specific volume breakdowns [78]

AtriCure (NasdaqGM:ATRC) Q4 2025 Earnings call February 17, 2026 04:30 PM ET Company ParticipantsAngie Wirick - CFODanny Stauder - Director of Equity Research in Medical TechnologyJohn McAulay - Associate VPMarissa Bych - Managing DirectorMike Carrel - President and CEOConference Call ParticipantsLily Lozada - Equity Research AnalystMarie Thibault - Managing Director and Medical Technology and Digital Health AnalystMike Matson - Senior AnalystSuraj Kalia - Managing Director and Senior Analyst in Medical Tec ...

TechPrecision (NasdaqCM:TPCS) Q3 2026 Earnings call February 17, 2026 04:30 PM ET Company ParticipantsAlex Shen - CEOBrett Maas - Managing DirectorJohn Brandberg - Managing MemberPhil Podgorski - CFORoss Taylor - Partner and Portfolio ManagerOperatorGreetings, and welcome to the TechPrecision Corporation Fiscal 2026 third quarter financial results. At this time, all participants are placed on a listen-only mode. As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, ...

Medifast (NYSE:MED) Q4 2025 Earnings call February 17, 2026 04:30 PM ET Company ParticipantsDan Chard - Chairman and CEOJim Maloney - CFONick Johnson - PresidentSteven Zenker - VP of Investor RelationsConference Call ParticipantsJim Salera - Research AnalystOperatorGreetings, and welcome to the Medifast fourth quarter 2025 earnings conference call. At this time, all participants are in a listen-only mode. A brief question and answer session will follow the formal presentation. Should anyone require operator ...

Beta Bionics (NasdaqGM:BBNX) Q4 2025 Earnings call February 17, 2026 04:30 PM ET Company ParticipantsBlake Beber - Head of Investor RelationsDavid Roman - Managing Director and Co-Head Healthcare Business UnitJeffrey Cohen - Managing Director and Director of Equity ResearchJon Block - Managing DirectorMatthew Blackman - Managing DirectorSean Saint - CEOStephen Feider - CFOConference Call ParticipantsDanielle Antalfy - Senior AnalystFrank Takkinen - Senior Research AnalystJeff Johnson - Managing Director and ...

Palo Alto Networks (NasdaqGS:PANW) Q2 2026 Earnings call February 17, 2026 04:30 PM ET Company ParticipantsAdam Borg - Managing DirectorAdam Tindle - Managing DirectorBrad Zelnick - Managing DirectorDipak Golechha - CFOGabriela Borges - Managing Director and Head of US Software Equity ResearchGregg Moskowitz - Managing DirectorHamza Fodderwala - SVP of Investor Relations and Strategic FinanceJohn DiFucci - Senior Managing DirectorJosh Tilton - Managing DirectorLee Klarich - Chief Product and Technology Offi ...

Financial Data and Key Metrics Changes - Total revenue for 2025 grew by 38% to $1.4 billion, with royalty revenue increasing by 52% to $868 million, reflecting strong performance from ENHANZE-enabled products [9][17] - Net income for the full year was $316.9 million, down from $444.1 million in 2024, impacted by a $285 million acquired IP R&D expense [19] - Adjusted EBITDA was $657.6 million, compared to $632.2 million in 2024, indicating operational strength despite the IP charge [19] Business Line Data and Key Metrics Changes - DARZALEX Subcutaneous generated $483 million in royalty revenue, a 29% year-over-year growth, with total sales reaching $14.4 billion [10] - PHESGO's royalty revenue increased by 51% to $105.6 million, with total sales growing 48% year-over-year to approximately $3 billion [11] - VYVGART and VYVGART Hytrulo saw a 444% year-over-year growth in royalty revenues to $157.2 million, with total sales reaching $4.15 billion [12] Market Data and Key Metrics Changes - ENHANZE now has 10 global blockbuster opportunities, with significant approvals in the U.S., Japan, and China for various products [8][16] - The subcutaneous formulations of Ocrevus, Opdivo, RYBREVANT, and Tecentriq represent a combined market opportunity of approximately $30 billion by 2028 [13] Company Strategy and Development Direction - The company aims to expand its ENHANZE pipeline, projecting 6 new programs to enter phase one in 2026, bringing the total development portfolio to 15 products [24] - The strategy includes pursuing additional licensing agreements and evaluating new drug delivery technologies to enhance long-term revenue streams [27][28] - Hypercon technology is expected to meet the demand for lower volume, auto-injector-ready therapies, with projections of approximately $1 billion in royalty revenue within five years of the first launches [26] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the long-term trajectory of the company, emphasizing the durability of royalty revenue and the potential for exceptional value creation [23] - The company anticipates continued strong growth driven by existing products and new collaborations, with a focus on expanding into new therapeutic areas [25][36] Other Important Information - The company completed acquisitions of Elektrofi and Surf Bio, enhancing its drug delivery capabilities and extending IP into the mid-2040s [6][27] - The balance sheet was strengthened with the issuance of convertible notes and an upsized revolving credit facility, reducing near-term refinancing risk [21] Q&A Session Summary Question: Regarding the DARZALEX collaboration with J&J - Management expects to enter discussions with J&J to extend the agreement closer to its expiration in 2032, emphasizing the importance of the partnership [42] Question: On the ADC strategy and regulatory paths - The regulatory pathway for converting ADCs from IV to subcutaneous is expected to follow traditional PK non-inferiority studies, with additional trials for unapproved products [50] Question: Update on Hypercon products and clinical testing - Two Hypercon products are on track for phase 1 clinical testing in 2026, with completion of clinical scale-up batches and IND filings underway [66] Question: Potential incremental royalty opportunities from Merus's petosemtamab - Management highlighted the potential for expanded indications and the importance of subcutaneous formulations in enhancing patient treatment experiences [58]

Goosehead Insurance (NasdaqGS:GSHD) Q4 2025 Earnings call February 17, 2026 04:30 PM ET Company ParticipantsDan Farrell - VP of Capital MarketsMark Jones Jr. - CFO and COOMark Miller - President and CEOConference Call ParticipantsAndrew Andersen - Equity Research AnalystAndrew Kligerman - Equity Research AnalystBrian Meredith - Equity Research AnalystKatie Sakys - Equity Research AnalystMark Hughes - Equity Research AnalystMichael Zaremski - Equity Research AnalystPablo Singzon - Equity Research AnalystPaul ...